A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised Clinical Trial

Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants

Status Terminated

Clinical Trial Summary

The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: - To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population - To characterize concentrations of casirivimab and imdevimab in serum over time - To assess the immunogenicity of casirivimab and imdevimab

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05074433
Study type	Interventional
Source	Regeneron Pharmaceuticals
Contact
Status	Terminated
Phase	Phase 3
Start date	October 25, 2021
Completion date	May 18, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01258023` - Seasonal Flu Vaccine in Adult Transplant Recipients	Phase 2
Recruiting	`NCT03808922` - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study	Phase 3
Completed	`NCT03262584` - Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Recruiting	`NCT01301755` - Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration	N/A
Recruiting	`NCT03425526` - Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease	Phase 1
Terminated	`NCT02057289` - A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis	Phase 1
Active, not recruiting	`NCT03168815` - Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy	N/A
Terminated	`NCT01069601` - H1N1sw Vaccine in Adult Transplant Recipients	Phase 2
Withdrawn	`NCT05545319` - A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19	Phase 2
Completed	`NCT05020145` - COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States